Posts Tagged :

radiology

ESOR_QUIBIM Course

QUIBIM provides the platform for the GALEN Advanced Course organized by European School of Radiology

  • QUIBIM provided the software for the hands-on workshop activities, allowing a much more dynamic and interactive case discussion

QUIBIM was honored with the chance to participate in the last edition of the “GALEN Advanced Course on Oncologic Imaging of the Abdomen”. The event was organized by the European School of Radiology (ESOR), the educational initiative of the European Society of Radiology (ESR).

This course was aimed at senior residents, board-certified radiologists and fellows interested in abdominal oncologic imaging and focused on the application of the latest technical advancements and the new European guidelines for imaging.

ESOR_QUIBIM PrecisionQUIBIM provided the software for the hands-on workshop activities, allowing a much more dynamic and interactive case discussion. Based on our QUIBIM Precision® cloud Platform, this tool provides a powerful framework for the creation of new users, the uploading of imaging studies and relevant documentation and for the administration of the course.

Furthermore, the platform has been developed to provide lecturers with convenient features to share studies with students, visualize and edit them using our zero-footprint embedded DICOM Web Viewer and, most important, analyze the studies with any of the imaging biomarker plugins available at QUIBIM Precision®.

This event represents a great milestone for QUIBIM, as ESOR, with over 19.000 participants in more than 250 ESOR courses, has become the major provider of complementary radiological education in Europe and worldwide.

ESOR_QUIBIM

QUIBIM_chest_xray_classifier_logo3

New Chest X-Ray Classification Tool

Despite the technological evolution of imaging modalities like CT, US and MRI, conventional X-ray remains the most performed examination in radiology departments, and remains a fundamental tool for anatomical analysis in the detection and diagnosis of respiratory diseases and bone tissue alterations. However, radiology departments have limitations in reporting the X-Rays due to the limited resources available (link).

QUIBIM has developed a Chest X-Ray Classification Tool that offers a solution to this problem which can help radiology departments become even more efficient. This classifier developed in collaboration with Hospital Universitario y Politécnico La Fe, estimates the probability of chest X-Rays of having a pathology using Artificial Intelligence.

How does it work?

This tool makes use of fourteen Convolutional Neural Networks trained with a database of more than 100,000 images (NIH ChestXray14 dataset) to estimate the probability of presence of the following pathologies in chest X-Rays: atelectasis, cardiomegaly, effusion, infiltration, mass, nodule, pneumonia, pneumothorax, consolidation, edema, emphysema, fibrosis, pleural thickening and hernia. Afterwards, the probabilities are used by a Fully Connected Neural Network to get the final probability of the X-Ray of being abnormal.

Because of this AI methodology the classifier understands the visual patterns that are most indicative of the different pathologies using the knowledge extracted from the large dataset of radiographs used to train the networks. QUIBIM’s Chest X-Ray Classification Tool is able to learn further using new images, which means that this system is continually improving and evolving with time.

 What information does it provide?

Once all the quantifications are performed this tool provides an intuitive Structured Report with the patient’s information, the abnormal probability of the radiographs analyzed and the representation of the findings. In addition, if the image is classified as abnormal, the report shows the three pathologies that are more likely to be found and a heatmap that highlights the most abnormal regions. This report is designed to be very user friendly, to assist the user in understanding the tool’s findings at a glance in order to make its usage highly efficient.

Why is this new tool so useful?

Using this technology it is possible to prioritize unreported, potentially pathological radiographs which allows radiologists to focus their efforts on studies that are more likely to have pathologies and thereby become more efficient. This tool essentially ensures that pathological findings, which could have been unreported due to the heavy workload of radiology departments, are correctly reported.

QUIBIM’s goal is to provide the radiology departments with an optimal solution for automatic reading of X-Rays without interfering in the  workflow of the department.

QUIBIM’S Chest X-Ray Analysis Tool is already available at QUIBIM Precision® Depending on the needs of the department, this tool is accessible through the cloud with just a few clicks  or  it can be fully integrated in the radiology department’s workflow as a local solution for  seamless interpretation of  chest X-Rays.

boton try quibim

ESGAR Conference CCD Dublin Ireland 2018.

Co-Founder Prof. Luis Martí-Bonmatí receives ESGAR Gold Medal

During the 29th Annual Meeting and Postgraduate Course of ESGAR (European Society of Gastrointestinal and Abdominal Radiology) held in Dublin, our co-founder, Prof. Luis Marti-Bonmati received the ESGAR Gold Medal, the society’s highest award for outstanding contributions to the scientific community.

All QUIBIM team is proud and honoured. We congratulate Prof. Martí-Bonmatí on this achievement.

ESGAR Conference CCD Dublin Ireland 2018.

ESGAR Conference CCD Dublin Ireland 2018.

Photo credit: Roger Kenny Photography

Photo legend (from left to right): Steve Halligan (ESGAR President), Luis Martí-Bonmatí (Gold Medallist), Celso Matos (ESGAR Past President), Helen Fenlon (ESGAR Meeting President 2018).

Link to Insights into Imaging post: https://www.i3-journal.org/news/esgar-goldmedal/

 

Ines Perea, Strategic Advisor at QUIBIM

Quibim’s Strategic Advisor Inés Perea discusses the radical disruptions that quantitative imaging analysis can provide to cancer research

Quibim’s Strategic Advisor Inés Perea discusses the radical disruptions that quantitative imaging analysis can provide to cancer research amongst other areas

Inés Perea is a Doctor that graduated with honors in the Pharmacy and Executive Business Program by Instituto de Empresa of Madrid. Mrs. Perea has extensive and versatile experience spanning more than 20 years in the Pharmaceutical industry working within different roles within the Medical, Access and Commercial (Marketing, Sales, Strategic Planning) areas and international experience in Global and regional teams. Her main area of expertise is oncology and biologics where she has been involved in the strategic planning and commercialization of more than 10 drugs/indications, most of them linked to some form of biomarker diagnosis.

How did you come to know QUIBIM before becoming their strategic advisor?

I was in contact with founder and CEO, Angel Bayarri months prior to my start with Quibim. A mutual friend of ours, a director of a large genetics biomarker laboratory in Spain was working specifically on oncology genetic biomarker testing and I would get involved with his organization in the arenas of strategic value and development, as those are two of my core competencies. I was involved in the development and strategic value of genetic/biologic biomarkers in clinical trials in oncology. It was back in the 90’s when biomarkers were a thing of science fiction. Well, he introduced me to Angel and I really thought he had a fantastic idea when it came to implementation of 3-d imaging biomarkers and using algorithms to quantitatively analyze tumors. Once I learned about Quibim’s technology, I knew that the growth could be exponential if he partnered with strategic partners.

Your field of expertise is Oncology. The Quantitative Medical Imaging field has evolved significantly but we still use RECIST criteria for evaluation of treatment responses, what do you think is the main reason for this? Standardization?

This is the foundation for therapeutic trials. It is a standard when examining patients, however, it has some practical limitations. For example, with the latest breakthrough area in oncology research, immunotherapy, many immuno-oncology drugs are known to cause fluctuations in tumor size, which when analyzed simply with RECIST criteria, would appear as an increase to the tumor size, but it is now understood that tumor fluctuations occur regularly during immunotherapy treatments, often causing the tumor to grow prior to cell DE progression, which is in fact a good sign that would be captured with RECIST criteria well after the fact. In those cases, RECIST does not allow for factoring in the context of the holistic viewpoint that quantitative digital image analysis would facilitate.

What therapeutic indications are best served by incorporating quantitative imaging analysis into clinical research trials?

There is a very simple answer to this question: any therapeutic indication where standardized radiological assessments are a primary or secondary safety or efficacy endpoint of a study. This includes solid tumors, liver diseases, brain diseases, lung diseases, and many others.

Let’s discuss costs. Quantitative imaging analysis sounds expensive. However, automation and extraction of biomarkers as soon as a hospital acquires and uploads images related to a clinical trial can and do have a macroeconomic effect of lowering costs, therefore long-term costs decrease. What do you respond with when someone brings up this objection?

You are right, it is a tremendous cost saver from a macroeconomic point of view. What will continue to help this cause are national health systems, private funding, insurers, and other payers to see the long-term cost savings and efficiencies that quantitative imaging analysis facilitates. Essentially, we need to get quantitative image analysis included in the health system reimbursement system much like traditional biomarkers of a decade ago. As a matter of fact, it took health systems quite a bit of time to include standard biomarkers that we have all grown accustomed to, included on their reimbursement schedules. While it essentially all boils down to payers and health authorities, us researchers and technology pioneers need to continue to prove medium and long-term efficiencies and validate it with radiologists, clinicians and imaging researchers. Once we are able to do that effectively, the market will adjust accordingly, it always does.

The value seems to be in real-time results that can help in both safety and efficacy outcomes. Please expand further on this thought.

Real time results are everything if you really think about it. The main benefit is obviously how this technology facilitates the real time patient care capabilities of healthcare practitioners. Safety and efficacy instant results from treatments are critical when analyzing real time clinical research data. Imaging biomarkers can and will play a tremendous role in improving patient standard of care, and ultimately can make a real impact on disease outcomes.

by: Dan Sfera, also available at: https://medium.com/quibim/quibims-strategic-advisor-in%C3%A9s-perea-discusses-the-radical-disruptions-that-quantitative-imaging-54cef3a3e082

QUIBIM Imaging Biomarkers made transparent

QUIBIM, AI imaging disruption to showcase the value of Precision

We are in the era of Precision Medicine, and so is Radiology. Nowadays, main imaging modalities like X-ray, computed tomography (CT), magnetic resonance (MR), positron emission tomography (PET) and hybrid machines, among others, have become measurement instruments. Images are not only pictures anymore, but thanks to the application of computational analysis and artificial intelligence, they are data, as you can learn in this excellent manuscript in Radiology.

Nowadays, when radiologists perform measurements of different organs, tissues and lesion properties using a workstation, they are used to get a number (i.e. lesion volume or perfusion). If they take the same images and they get to analyze them in a workstation from another vendor (not straightforward), it is pretty sure that they will obtain different results. This issue has introduced a sense of lack of standardization and homogenization in the quantitative medical imaging field.

I like to say that value is to trust in the product, and we have decided to be the first company in the world to open the validation process and tests results of our imaging biomarkers. Every time we buy a measurement device for daily life purposes (i.e. thermometer) we know the degree of uncertainty, why wouldn’t we do the same in AI algorithms and quantitative imaging?

We are proud to make this announcement at ECR 2018: Now it is possible to see the precision, accuracy and clinical evaluation results of our imaging biomarkers. We provide the precision (through Coefficient of Variation, CoV) and accuracy (through relative error, e) values through the publication of QUIBIM Technical Datasheets that you can find in the resources section of our webpage.

With this strategy QUIBIM is going a step further by being the first multi-vendor, web-based and real precision Medicine company of the medical imaging & AI market.

Concerned by the accuracy of your measurements? Let’s work together.

Quibim Team

QUIBIM SIGUE CRECIENDO CON LA ENTRADA DE ANGELS EN SU CAPITAL

  • En 2015 fue una de las 27 startups aceleradas en la 3ª edición del programa Lanzadera.

  • Quibim es una Spin-Off del Instituto de Investigación Sanitaria La Fe.

Valencia, 28/07/17.- La empresa biotecnológica Quibim se refuerza mediante la entrada de Angels – la sociedad de inversión perteneciente a Marina de Empresas e impulsada por el empresario Juan Roig – en el capital social de la compañía.

Tras la ronda a finales de 2016 con el Fondo de Inversión Tecnológico Tech Transfer UPV, AYCE Capital, Bioinfogate y los promotores del proyecto; y la ayuda H2020 Instrumento Pyme Fase II, de la que ha sido beneficiaria recientemente; Quibim recibe el apoyo de Angels, que participa en la empresa mediante la capitalización del préstamo que la compañía tenía con Lanzadera.

Impulsada por Ángel Alberich Bayarri, CEO, y el Dr. Luis Martí Bonmatí, radiólogo de reconocido prestigio internacional, director del Área Clínica de Imagen Médica del Hospital Universitario y Politécnico La Fe de Valencia y actual director del Consejo Científico de la empresa; la compañía está formada en la actualidad por 11 personas.

Quibim es una empresa biotecnológica especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma Quibim Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, Quibim es capaz de aplicar avanzados algoritmos de análisis que incluyen metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de Quibim permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos.

Según afirma Ángel Alberich-Bayarri, “La entrada de Angels en la compañía es para nosotros una gran satisfacción, ya que se materializa la relación iniciada en nuestro paso por Lanzadera, cuya ayuda fue imprescindible para hacer este proyecto realidad”.

El Director General de Angels, Jaime Esteban, añade, “Contar con Quibim entre las participadas de Angels afianza lo que Marina de Empresas quiere significar para los emprendedores: un lugar donde recibir apoyo en cualquier momento de su carrera, desde la formación hasta la inversión”.

 

Sobre Angels

Angels es la sociedad de inversión perteneciente a Marina de Empresas e impulsada por el empresario Juan Roig con capital 100% privado. Desde su constitución en septiembre de 2013, ha aportado a diferentes proyectos emprendedores más de 12 millones de € para que estas empresas de nueva generación puedan crecer y desarrollar su actividad. En la actualidad, Angels participa además de en Quibim, en Codigames, Grupo Sothis, Instituto Valenciano del Pie (IVPie), Grupo Vintes (Bodega Torre Oria), viVood y PlayFilm.

SMEInstrument

QUIBIM granted with the H2020 – SME Instrument Phase II

QUIBIM team is proud to announce that the beneficiaries of the European Commission SME Instrument Phase 2 have been recently published, and our project has been awarded in the Open Disruptive Innovation (ODI) topic.

QUIBIM’s project “QUIBIM Precision” has been granted with 1.25M€ for the scaling and development of the company business plan through our cloud platform QUIBIM Precision®. This funding will boost and accelerate the strategic plan of the company, bringing new disruptive solutions to our platform, including dedicated High Performance Computing resources for our Machine Learning processes, incorporating new visual analytics tools and helping validate new imaging biomarkers that have been recently developed.

QUIBIM Precision® is an innovative imaging biomarker analysis platform in the cloud allowing for:

  1. Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility.
  2. Medically certified: QUIBIM is medically valid to scientifically support decision making.
  3. Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities.
  4. Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis.

Our technology based on machine learning and image processing algorithms scouts the image and compares it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye.

About QUIBIM
QUIBIM is a biotechnology company dedicated to advanced medical image analysis. It was one of the start-ups selected in the 3rd edition of the acceleration program “LANZADERA” and it’s a spin-off company of the Medical Research Institute Hospital La Fe. Recently the company closed an investment round to boost its growth, including Tech Transfer UPV, AYCE Capital, and BioInfoGate, as well as some company promoters . QUIBIM’s business model is based on the extraction of quantitative information from radiological and nuclear medicine imaging using original and advanced computational processing techniques.

In 2016, QUIBIM was also selected as one of the disruptive companies by the EU and granted with the first round of Horizon 2020 SME Instrument Phase I Program 2016 under the call: “SMEInst-01- 2016-2017: Open Disruptive Innovation Scheme”

SME instrument – Horizon 2020 call
The SME Instrument is divided into 3 phases covering different stages of the innovation cycle. Phase 1 aims to cover the assessment of technical feasibility and market potential of new ideas. The project will be supported by an investment of 50,000€ and the typical duration should be no longer than 6 months.

Phase 2 aims to cover R&D activities with a particular focus on demonstration activities (testing, prototype, scale-up studies, design, piloting innovative processes, products and services, validation, performance verification etc.) and market replication encouraging the involvement of end users or potential clients. Project funding should amount to no more than 2,500,000€ and the typical duration of this phase should range from 12 to 24 months.

3D_Full_Low_Both

Assessing the bone quality of your patients is just a few clicks away

Quibim is proud to introduce its new advanced methodolgy to assess bone quality and fracture risk: QTS (Quality of Trabecular Structure). The need for a reliable approach for the characterization of trabecular microarchitecture is evident, as conditions and diseases related to trabecular bone quality and structure are becoming a focal point of precision medicine. Millions of dollars are spent in bone fracture care and prevention, which in many cases represent a grave danger to the patient health. In this scenario, can we rely upon available methods to predict bone fractures? Regrettably, the answer is no. Or so it was. Before we introduce QTS in detail, let’s first review some of the available methods to evaluate fracture risk.

DEXA Bone Mineral Density (BMD) limitations as a fracture predictor are widely known. However, despite its glaring shortcomings it’s still considered as the gold standard in clinical practice. The WHO developed the FRAX tool hoping to improve the low ratio of success of BMD as a predictor, and, while it improves sensibility and specificity assessing fracture risk, it’s still not satisfactory enough for it to be used as a stand-alone predictor in clinical practice or clinical trials.

In an attempt to fill this void in the search of a reliable predictor, new imaging biomarkers that guarantee to provide the needed sensibility and specificity have been developed. Trabecular Bone Score (TBS®) by Medimaps is a fracture risk predictor using DEXA as a source. TBS® performs a gray level analysis (textures) on the DEXA images to determine bone integrity. But, is DEXA adequate for this task? Unlike regular XR, in which it’s possible to assess the trabecular structure, DEXA’s low radiation is not enough for trabeculae differentiation. In addition, DEXA (like XR) represents a 3D structure as a projection onto a plane, losing spatial information.

Other medical imaging modalities are much more adequate for bone analysis and the subsequent fracture risk evaluation. Thanks to advanced computing models, Quibim has developed a new imaging biomarker that uses either magnetic resonance (MR), computerized tomography (CT) or X-ray imaging for a detailed characterization of the trabecular structure. QTS (Quality of Trabecular Structure) by Quibim introduces several advantages over other analysis methods:

  • Real extraction of the trabecular bone microarchitecture: bone volume, trabecular thickness, trabecular separation…
  • Information of the complexity of the structure: fractal analysis
  • 3D spatial information, not only in plane (only CT and MR)
  • 3D reconstruction of the trabecular bone (only CT and MR)
  • Optional mechanical analysis (only CT and MR, with QTS+)
  • QTS Score comprises all this information in a single score for a rapid and accurate characterization of the bone structure.

This groundbreaking analysis method is already available at our cloud web platform: Quibim Precision. Below we detail how to analyze your study in a few simple steps.

Quibim Precision allows the upload of studies in Dicom format. The upload process is easy, intuitive and 100% secure, guaranteeing the patient confidentiality thanks to Quibim’s anonymization and encryption system. The whole process is performed without the need of installing any additional software. To start, click on the green “Upload Study” button to the right of the website.

00

The platform will then ask for Dicom studies selection. With Google Chrome, we can drag and drop the study folder directly to the dotted box. With any other browser, we need to select the Dicom files to be uploaded.

00b

Once the Dicom folders have been selected, Quibim Precision allows the pre-visualization of the study to choose which sequences we wish to upload. In this case, we need a CT, an X-ray or a 3D T1 MR.

After the selection, the files will be anonymized and encrypted. Quibim Precision will ask for an encryption password before the upload process starts. The user needs to preserve this password, as it’s needed for patient traceability.

00c

After the upload process is completed, we click on the “Analyze Study” button of the study we want to evaluate.

01

This will take us to the detailed view of the study, where we can perform all actions related to it. First of all, we will choose among all the available sequences the one to be analyzed and its Quibim standard name. In this case, the name of the sequence is “Linear Attenuation [1/cm] (3035)”, which corresponds to the standard name “High Resolution CT”.

02

Next, we open the embedded Dicom viewer by clicking on “View”. Thanks to this viewer we can draw the ROI that will be used for the analysis. The viewer allows drawing 3D ROIs, first drawing a 2D rectangular ROI, and then selecting the slices on which it should be replicated. Clicking on “Apply” and “Save and go back” will store the ROI and it will be used for the analysis.

04b

Finally, we should choose which analysis method we’ll use among all the available apps in Quibim Precision. In this case we’ll click on the “Start Analysis” button of the “3D Bone microarchitecture – QTS Score” app. The analysis process will then start, and the user doesn’t need to perform any other action than checking the results.

03

The results of the analysis are available on the view of the study. Once the analysis is completed we can check them by clicking on the “View Study” button on the “Processed Biomarkers” section.

05

We can examine the 3D reconstruction images and the numeric results of the extracted imaging biomarkers on the results view. Furthermore, we can download them and the structured report in pdf format, which includes all the generated data in a compact, easy to read way.

06

07b

08

All the benefits of QTS are just a few clicks away. Create an account on Quibim Precision and start offering a real added value with your imaging studies.

Try us for free!